Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

MicroRNA-383-5p Predicts Favorable Prognosis and Inhibits the Progression of Diffuse Large B-Cell Lymphoma

The present study aims to investigate the role of miR-383-5p in DLCBL. 

Oncology Letters
Optimal Timing and Criteria of Interim PET in DLBCL: A Comparative Study of 1692 Patients

The aim of this study is to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. 

Blood Advances
New CAR-T Approach Minimizes Resistance in B-Cell Lymphoma

Early results from a new CAR T-cell immunotherapy trial led by researchers find that using a bilateral attack instead of the conventional single-target approach helps minimize treatment resistance.

Oncology Times - Latest Articles

Infection-Related Morbidity and Mortality Among Older Patients With DLBCL Treated With Full- or Attenuated-Dose R-CHOP

Increased risk of infection-related hospital admission is independently associated with IDI >80% in older patients with DLBCL.

Blood Advances
Long-Term Outcomes of R-CEOP Show Curative Potential in Patients With DLBCL and a Contraindication to Anthracyclines

The R-CEOP regimen is a valid alternative to R-CHOP for patients with de novo DLBCL and an absolute contraindication to anthracyclines.

Blood Advances
Efficacy and Safety of Prophylactic High-Dose MTX in High-Risk DLBCL: A Treatment Intent–Based Analysis

In high-risk DLBCL patients, prophylactic HD-MTX does not improve CNS or survival outcomes but is associated with increased toxicities.

Blood Advances
A Rare Cause of Acute Liver Failure Due to Haemophagocytic Lymphohistiocytosis Secondary to Diffuse Large B-Cell Lymphoma

This is a case report of a 74-year-old man with acute liver failure secondary to haemophagocytic lymphohistiocytosis triggered by undiagnosed large B-cell lymphoma.

Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma

The goal of this study is to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo/R-CHOP in previously untreated, ABC-type DLBCL.

Journal of Clinical Oncology
CARs Are the Ride of the Future for Curing DLBCL

CAR T-cell therapy has the potential to cure the most diffuse large B-cell lymphoma patients who have recurrent disease.

Oncology Times - Latest Articles
Functional Characterization of PD1+TIM3+ Tumor-Infiltrating T Cells in DLBCL and Effects of PD1 or TIM3 Blockade

Activated B cell–like DLBCL shows increased levels of PD1+TIM3+ TILs with impaired functions.

Blood Advances
Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

To explore the genetic mechanisms underlying treatment resistance in rrDLBCL and to identify candidate genes, study investigators perform targeted deep sequencing of 430 lymphoma-related genes...

Frontiers in Oncology
Establishment of a Typing Model for Diffuse Large B-Cell Lymphoma Based on B-Cell Receptor Repertoire Sequencing

The purpose of this study is to construct a new typing model for DLBCL patients based on the B-cell receptor and explore its potential molecular mechanism.

BMC Cancer
GM-CSF Enhanced the Effect of CHOP and R-CHOP on Inhibiting Diffuse Large B-cell Lymphoma Progression via Influencing the Macrophage Polarization

In the present study, the combination use of CHOP and R-CHOP with GM-CSF is used to evaluate their effects on the tumor immune microenvironment of DLBCL.

Cancer Cell International
Impact of Organ Function–Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma

Exclusion of patients needing urgent treatment or requiring novel biomarkers before enrollment has impacted the ability to enroll real-world patients in frontline trials of DLBCL.

Journal of Clinical Oncology
Identification of Super Enhancer-Associated Key Genes for Prognosis of Germinal Center B-cell Type Diffuse Large B-cell Lymphoma by Integrated Analysis

This study aims to explore the regulation of super enhancers on GCB-DLBCL by identifying specific SE-target gene.

Identification and Validation of a Prognostic Gene Signature for Diffuse Large B-Cell Lymphoma Based on Tumor Microenvironment-Related Genes

Study investigators perform a systematic investigation of the TME and genetic factors associated with DLBCL to identify prognostic biomarkers for DLBCL.

Frontiers in Oncology
Distribution of Chimeric Antigen Receptor-Modified T Cells Against CD19 in B-Cell Malignancies

The unprecedented efficacy of CAR-T cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumors.

BMC Cancer
Plasma Proteome Profiling of Cardiotoxicity in Patients With Diffuse Large B-Cell Lymphoma

This study aims to illustrate the incidence of CVD in DLBCL patients treated with DXR and to establish whether there are plasma proteins associated with pre-existing or emerging CVD.

5-Hydroxymethylcytosine Profiles of cfDNA are Highly Predictive of R-CHOP Treatment Response in Diffuse Large B Cell Lymphoma Patients

Although R-CHOP remains the standard chemotherapy regimen for DLBCL patients, not all patients are responsive to the scheme, and there is no effective method to predict treatment response.

Clinical Epigenetics
Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs

The aim of this study is to identify and compare circulating serum miRNA and peripheral whole blood miRNA profiles in patients with these lymphomas.

BioMed Research International
Role of Epstein–Barr Virus C Promoter Deletion in Diffuse Large B Cell Lymphoma

The C promoter of Epstein–Barr virus is assumed to be important for B cell growth and transformation, but this study presents evidence that promoter activity is not only unneeded...

Circulating RNA Biomarkers in Diffuse Large B-Cell Lymphoma

The aim of this systematic review is to present the current understanding of circulating RNA molecules as biomarker in DLBCL and to discuss their future potential.

Experimental Hematology & Oncology
Influence of Severe Gastrointestinal Complications in Primary Gastrointestinal Diffuse Large B-Cell Lymphoma

This study assesses the clinical characteristics of gastrointestinal bleeding, obstruction, and perforation in patients with PGI-DLBCL and the influence on long-term survival.

Soluble PD-1 But Not PD-L1 Levels Predict Poor Outcome in Patients With High-Risk Diffuse Large B-Cell Lymphoma

Study investigators use serum samples collected during a conduction of a prospective immunochemotherapy trial in patients with high-risk DLBCL and assess their clinical significance.

Importance of Diagnosis-to-Treatment Interval in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma

This study evaluates the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma. 

Scientific Reports
High Level of Pre-Treatment C-Reactive Protein to Albumin Ratio Predicts Inferior Prognosis in Diffuse Large B-Cell Lymphoma

This retrospective study evaluates the prognostic value of CAR in 186 DLBCL patients.

Scientific Reports
MATRix–RICE Therapy and Autologous Haematopoietic Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma With Secondary CNS Involvement

This study assesses the activity and safety of an intensive, CNS-directed chemoimmunotherapy consolidated by autologous HSCT in patients with secondary CNS lymphoma.

Primary Diffuse Large B-Cell Lymphoma of the Fallopian Tube Treated With a Combination of Surgery and Chemotherapy

The most common genital localizations are the cervix, the uterine corpus and the ovary, while primary lymphomas of the fallopian tube are quite unusual.

Diffuse Large B-Cell Lymphoma Originating From the Rectum and Diagnosed After Rectal Perforation During the Treatment of Ulcerative Colitis

GI lymphomas like DLBCL are rare complications of ulcerative colitis, and only a few studies have reported intestinal ulcers caused by DLBCL, which got perforated during the treatment of UC.

BMC Surgery
Gene Expression Profiling-Based Risk Prediction and Profiles of Immune Infiltration in Diffuse Large B-Cell Lymphoma

Recent studies suggest that the immune microenvironment plays a role in treatment response prediction and survival in DLBCL.

A Phase 2 Study of Venetoclax Plus R-CHOP as First-Line Treatment for Patients With Diffuse Large B-Cell Lymphoma

Venetoclax + R-CHOP showed potential for improved efficacy vs R-CHOP alone, supporting further investigation of venetoclax in Bcl-2+ DLBCL.

Circulating Long Non-Coding RNAs HOTAIR, Linc-p21, GAS5 and XIST Expression Profiles in Diffuse Large B-cell Lymphoma: Association With R-CHOP Responsiveness

This study investigates plasma lncRNAs; HOTAIR, Linc-p21, GAS5 and XIST as biomarkers for DLBCL diagnosis and responsiveness to R-CHOP therapy.

Scientific Reports
Development and Validation of a Novel Risk Stratification Model for Cancer-Specific Survival in Diffuse Large B-Cell Lymphoma

This study aims to develop a predictive nomogram and a web-based survival rate calculator that can dynamically predict the long-term cancer-specific survival of DLBCL patients.

Frontiers in Oncology
Clonal Evolution in Diffuse Large B-cell Lymphoma With Central Nervous System Recurrence

Study investigators collect paired samples from six patients with DLBCL with available biopsies from a lymph node at primary diagnosis and the CNS at recurrence.

Applying Probability Calibration to Ensemble Methods to Predict 2-Year Mortality in Patients With DLBCL

Study investigators develop a predictive model to predict the mortality hazard of DLBCL patients within 2 years of treatment.

Immune Reconstitution and Infectious Complications Following Axicabtagene Ciloleucel Therapy for Large B-Cell Lymphoma

This study evaluates the long-term course of hematologic recovery, immune reconstitution, and infectious complications in 41 patients with LBCL treated with axicabtagene ciloleucel at a single cent

Blood Advances
EHMT2 Inhibitor BIX-01294 Induces Endoplasmic Reticulum Stress Mediated Apoptosis and Autophagy in Diffuse Large B-Cell Lymphoma Cells

This study provides new evidence that EHMT2 may be a new therapeutic target, and BIX-01294 may be a potential therapeutic drug for treating DLBCL.

Notch Activation is Pervasive in SMZL and Uncommon in DLBCL: Implications For Notch Signaling in B-Cell Tumors

Notch receptors participate in a signaling pathway in which ligand-induced proteolysis frees the NICD, allowing it to translocate to the nucleus, form a transcription complex...

Blood Advances
Clinical Characteristics and Outcomes of Extranodal Stage I Diffuse Large B-Cell Lymphoma in the Rituximab Era

This retrospective study aimed to better define the characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.

Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma

The objective of this study is to evaluate the efficacy and safety of GemDOx with or without rituximab as salvage therapy in patients with relapsed or refractory DLBCL and PTCL.

Primary Diffuse Large B-Cell Lymphoma of the Female Urethra


Primary urethral non-Hodgkin’s lymphoma is uncommon. This case study reports the case of a 52-year-old woman with a light red mass at the urethral orifice.

Potential New Standard for High-Risk B-Cell Non-Hodgkin Lymphoma

DLBCL accounts for more than 60 percent of pediatric NHLs. Patients diagnosed with it have a 5-year survival rate of 63 percent for all disease stages combined.

Oncology Times - Latest Articles
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

This article reviews current strategies and novel therapies for relapsed/refractory DLBCL.

International Journal of Molecular Sciences
R2CHOP Benefits Patients With Untreated Diffuse Large B-Cell Lymphoma, Regardless of Subtype

For patients with previously untreated DLBCL, adding lenalidomide to the combination of R-CHOP reduces the risk of progression or death by 34%.

ASH Clinical News
Immunophenotypic Landscape and Prognosis of Diffuse Large B-Cell Lymphoma with MYC/BCL2 Double Expression: An Analysis of A Prospectively Immunoprofiled Cohort

DLBCL with MYC/BCL2 double-expression, a recently proposed poor prognostic group, can be easily identified by immunohistochemistry in routine clinical practice.

Socioeconomic Disparities in Diagnostic Testing Among Patients with Diffuse Large B-Cell Lymphoma in the US

Despite advances in treatment and increasing knowledge of clinical importance of DLBCL subtype classification, socioeconomic disparities persist in the treatment of DLBCL in the US...

The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma

This study recently reported a new tool to help the early identification of ultra-high risk DLBCL patients.

NUSAP1 Promotes Cell Proliferation Via the DNA Damage Response Pathway in Diffuse Large B-Cell Lymphoma

NUSAP1 has been shown to be highly expressed in a variety of tumors, involved in tumor occurrence, invasion, migration, and drug resistance.

Real-World CAR-T Therapy Toxicity in Patients With DLBCL

This study explores the toxicity from axicabtagene ciloleucel in the real-world setting demonstrates the necessity for more studies exploring real-world experience and data to define...

Journal of Clinical Pathways
Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tafasitamab is an Fc-enhanced, humanized, monoclonal antibody that targets CD19, which is broadly expressed across B-cell malignancies, including DLBCL.

Reductions in Rates of Surveillance Imaging in Patients With Diffuse Large B-Cell Lymphoma

Rates of surveillance imaging for survivors of DLBCL have declined following the ASH Choosing Wisely recommendations made in 2013.

Oncology Nurse Advisor
Melatonin increases the chemosensitivity of diffuse large B-cell lymphoma cells to epirubicin by inhibiting P-glycoprotein expression via the NF-κB pathway.

Epirubicin is a first-line chemotherapeutic drug for the clinical treatment of DLBCL, but the overexpression of multidrug resistance transporter proteins, especially P-glycoprotein...

Translational Oncology
Gingival manifestation of a therapy-related acute myelomonocytic leukemia in a patient with previously treated with R–CHOP scheme for diffuse large B-cell lymphoma

In this case, a 58-year-old patient diagnosed with DLBCL and treated with the CHOP-R therapeutic scheme, developed after 4 years a widespread gingival enlargement...

Oral and Maxillofacial Surgery Cases
Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV.

In this study, the authors conducted a retrospective review of DLBCL tissues from patients with and without HIV infection to compare expression of AID and B-cell receptors...


source list reference